X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Jardiance (empagliflozin) is an oral inhibitor of sodium-glucose co-transporter 2 (SGLT2) inhibitor, which is being evaluated for the treatment of myocardial infarction.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2024
Details:
Spevigo (spesolimab) is a novel, humanized, selective antibody that specifically blocks activation of the IL-36R, a signaling pathway within the immune system. It is approved for the treatment of generalized pustular psoriasis in adults and pediatric patients aged 12 & above.
Lead Product(s): Spesolimab
Therapeutic Area: Dermatology Product Name: Spevigo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Details:
The collaboration aims to focus on the development of HTL0048149, which is a GPR52 agonist. Currently it being evaluated with patients for the treatment of Schizophrenia.
Lead Product(s): HTL0039732
Therapeutic Area: Psychiatry/Psychology Product Name: HTL0039732
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Sosei Heptares
Deal Size: $732.5 million Upfront Cash: $27.3 million
Deal Type: Collaboration March 11, 2024
Details:
BI456906 (survodutide) is a glucagon/GLP-1 receptor dual agonist with a novel mechanism of action. It is being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Lead Product(s): Survodutide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BI 456906
Highest Development Status: Phase IIProduct Type: Peptide
Recipient: Zealand Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
NBL-001 (volasertib) is a PLK-1 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of relapsed/refractory acute myelogenous leukemia.
Lead Product(s): Volasertib
Therapeutic Area: Oncology Product Name: NBL-001
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Notable Labs
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
Jardiance (empagliflozin) is an oral inhibitor of sodium-glucose co-transporter 2 (SGLT2) inhibitor, which is indicated for the treatment of chronic kidney disease.
Lead Product(s): Empagliflozin
Therapeutic Area: Nephrology Product Name: Jardiance
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
Under the terms of the agreement, Boehringer Ingelheim will receive exclusive, worldwide rights from Kyowa Kirin to develop novel, first-in-class treatments for fibro-inflammatory diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Recipient: Kyowa Kirin
Deal Size: $441.8 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 05, 2024
Details:
Under the agreement, Boehringer will provide patient-derived T-cell receptor (TCR) data to fuel 3T's target discovery efforts to identify cognate antigens using its 3T TRACE discovery platform, to develop first-in-class immuno-oncology treatments.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Recipient: 3T Biosciences
Deal Size: $538.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 04, 2024
Details:
Under the agreement, Boehringer exercised its option to license a number of cancer antigens discovered and validated using Enara Bio’s Dark Antigen discovery platform, EDAPT® and intends to develop novel off-the-shelf vaccines against non-small cell lung cancer (NSCLC).
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Vaccine
Recipient: Enara Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 04, 2024
Details:
The collaboration aims to develop novel treatments for NASH/MASH by using Ribo's experience in the discovery and clinical development of siRNA therapeutics with Boehringer's commitment to improving the lives of people living with cardiovascular, renal and metabolic diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: Ribocure Pharmaceuticals
Deal Size: $2,000.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 03, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
